Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes

Sodium–glucose co-transporter 2 (SGLT2) inhibitors, such as canagliflozin, are used in patients with Type 2 diabetes mellitus (T2DM). In clinical studies, canagliflozin significantly reduced A1C, bodyweight and blood pressure, and was generally well tolerated with no increased risk of hypoglycemia....

Descripción completa

Detalles Bibliográficos
Autor principal: Kushner, Pamela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384506/
https://www.ncbi.nlm.nih.gov/pubmed/26928259
http://dx.doi.org/10.2217/whe-2016-0001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384506/
https://www.ncbi.nlm.nih.gov/pubmed/26928259
http://dx.doi.org/10.2217/whe-2016-0001

Ejemplares similares